AAN GUIDELINES Bundle

Amyotrophic Lateral Sclerosis

AAN GUIDELINES Product Bundle brought to you by Guideline Central.

Issue link: https://eguideline.guidelinecentral.com/i/322479

Contents of this Issue

Navigation

Page 5 of 5

Disclaimer is Guideline attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. is Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. e ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. 106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 For additional copies: info@GuidelineCentral.com Copyright © 2012 All rights reserved Source Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: e care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review). Neurolog y. 2009; 73(15):1218-1226. [PMID: 19822872] Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: e care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review). Neurolog y. 2009;73(15):1227-1233. [PMID: 19822873] Endorsed by the American Association of Neuromuscular and Electrodiagnostic Medicine. Abbreviations AAN, American Academy of Neurolog y; ALS, amyotrophic lateral sclerosis; bid, twice daily; BTxB, botulinum toxin type B; DM, dextromethorphan; FDA, Food and Drug Administration; FVC, forced vital capacity; h, hour(s); mg, milligram; MIE, mechanical insufflation/exsufflation; MIP, maximal inspiratory pressure; PCEF, peak cough expiratory flow; PEG, percutaneous endoscopic gastrostomy; Q, quinidine; q, every; SNP, sniff nasal pressure; TIV, tracheostomy invasive ventilation; VC, vital capacity Classification of Management Recommendations Classification Definition Strong (A) Established as effective, ineffective, or harmful (or established as useful/predictive or not useful/predictive) for the given condition in the specified population. (Level A rating requires at least two consistent Class I studies.)* Moderate (B) Probably effective, ineffective, or harmful (or probably useful/ predictive or not useful/predictive) for the given condition in the specified population. (Level B rating requires at least one Class I study or two consistent Class II studies.) Weak (C) Possibly effective, ineffective, or harmful (or possibly useful/ predictive or not useful/predictive) for the given condition in the specified population. (Level C rating requires at least one Class II study or two consistent Class III studies.) Insufficient (U) Data inadequate or conflicting ; given current knowledge, treatment (test, predictor) is unproven. *In exceptional cases, one convincing Class I study may suffice for an "A" recommendation if 1) all criteria are met, 2) the magnitude of effect is large (relative rate improved outcome > 5 and the lower limit of the confidence interval is > 2).

Articles in this issue

Links on this page

view archives of AAN GUIDELINES Bundle - Amyotrophic Lateral Sclerosis